Drug / Drugs / Boston blog main / Boston top stories / Boulder / Denver blog main / Denver top stories / Detroit blog main / Detroit top stories / Indiana blog main / Indiana top stories / National / National blog main / National top stories / New York blog main / New York top stories / Raleigh-Durham blog main / Raleigh-Durham top stories / San Diego blog main / San Diego top stories / San Francisco blog main / San Francisco top stories / Seattle blog main / Seattle top stories / Texas blog main / Texas top stories / Wisconsin blog main / Wisconsin top stories / ACA / Acquisition / Administration / Affordable Care Act / Aimovig / Alnylam Pharmaceuticals / Amgen / AML / Approval / Ascletis / Astex Pharmaceutials / BioDelivery Sciences International / Biogen / Biotech / BMS / Bristol-Mysers Squibb / cell gene therapy / ceo / China / clinical trials / Competition / Contrave / Costs / data / Deal / departure / Donald Trump / drug prices / Epizyme / erenumab / European Commission / failure / FDA / fired / Food and Drug Administration / fundraising / guadecitabine / hATTR / hereditary transthyretin amyloidosis / hikes / Hong Kong / Ian Read / importation / insurance / iobenguane / IPO / Karuna Pharmaceuticals / Keytruda / Lawsuit / Life Sciences / Lung Cancer / M&A / Metastatic Melanoma / Nivolumab / Novartis / Obamacare / Oncorus / Onpattro / Opdivo / Orexigen Therapeutics / Otsuka / patisiran / PBMs / pembrolizumab / Pernix Therapeutics / Pfizer / pharmacy benefit managers / Progenics Pharmaceuticals / rebates / Recruitment / regulation / reviral / RNA Interference / RNAi / rsv / Schizophrenia / Shefali Agarwal / Sienna Biopharmaceutics / skinny / SNA-001 / Software / SQZ Biotech / Stabilizing / stable / Ted Ashburn / Thomas Hughes / Thomas Smith / VC / Venture Capital / Verana Health / whistleblower / White House / Zafgen

Bio Roundup: Alnylam's Moment, Read on Rebates, Skinny Plans & More

Posted on: Aug 3, 2018   |   Posted by: Biotech Mag

Bio Roundup: Alnylam's Moment, Read on Rebates, Skinny Plans & More

Millions of people might be on vacation as we hit the dog days, but drug makers and politicians aren't taking a break from the gamesmanship over high drug prices. After two...

Continue reading ...